Table 1.
Characteristics of the Patients at Initial Banking and Univariate Associations with Disease Progression.*
| Variable | All Patients (N = 86) | Disease Progression (N = 35) | No Disease Progression (N = 51) | Disease Progression or Death (N = 60) | Disease Progression | Disease Progression or Death | ||
|---|---|---|---|---|---|---|---|---|
| Hazard Ratio (95% CI) | P Value† | Hazard Ratio (95% CI) | P Value‡ | |||||
| number of patients | ||||||||
| Age at transplantation | ||||||||
| ≤60 yr | 48 | 16 | 32 | 28 | 1.60 (0.83–3.08) | 0.16 | 1.77 (1.05–2.97) | 0.03 |
| >60 yr | 38 | 19 | 19 | 32 | ||||
| IPSS-R score | ||||||||
| Very low | 1 | 0 | 1 | 0 | 1.55 (1.04–2.30) | 0.03 | 1.20 (0.92–1.57) | 0.18 |
| Low | 14 | 4 | 10 | 7 | ||||
| Intermediate | 13 | 3 | 10 | 9 | ||||
| High | 30 | 11 | 19 | 21 | ||||
| Very high | 19 | 12 | 7 | 15 | ||||
| Missing data | 9 | 5 | 4 | 8 | ||||
| Type of MDS | ||||||||
| Primary MDS | 40 | 15 | 25 | 23 | ||||
| Therapy-related MDS | 25 | 11 | 14 | 18 | 1.19 (0.56–2.55) | 0.65 | 1.48 (0.80–2.76) | 0.22 |
| Secondary AML§ | 21 | 9 | 12 | 19 | 1.08 (0.48–2.45) | 0.85 | 1.98 (1.07–3.64) | 0.03 |
| Poor-risk gene or pathway¶ | ||||||||
| RAS pathway | 14 | 7 | 7 | 11 | 0.99 (0.51–1.92) | 0.97 | 1.03 (0.54–2.00) | 0.92 |
| TP53 | 16 | 11 | 5 | 14 | 2.77 (1.41–5.44) | 0.003 | 1.98 (1.09–3.63) | 0.03 |
| RUNX1 | 17 | 9 | 8 | 11 | 1.67 (0.79–3.56) | 0.18 | 0.98 (0.51–1.88) | 0.94 |
| ASXL1 | 19 | 8 | 11 | 13 | 1.21 (0.55–2.64) | 0.64 | 1.13 (0.61–2.10) | 0.70 |
| Conditioning regimen | ||||||||
| Myeloablative | 50 | 15 | 35 | 34 | 0.40 (0.21–0.78) | 0.007 | 0.73 (0.44–1.22) | 0.23 |
| Reduced intensity | 36 | 20 | 16 | 26 | ||||
| Day 30 variant allele frequency | ||||||||
| <0.5% | 54 | 14 | 40 | 33 | 3.65 (1.88–7.09) | <0.001 | 2.07 (1.24–3.46) | 0.005 |
| ≥0.5% | 32 | 21 | 11 | 27 | ||||
| Day 100 variant allele frequency in 58 patients | ||||||||
| <0.5% | 40 | 9 | 31 | 21 | 6.04 (2.53–14.44) | <0.001 | 2.46 (1.24–4.88) | 0.01 |
| ≥0.5% | 18 | 13 | 5 | 14 | ||||
| NA | 28 | 13 | 15 | 25 | ||||
*
AML denotes acute myeloid leukemia, CI confidence interval, IPSS-R Revised International Prognostic Scoring System, MDS myelodysplastic syndrome, and NA not applicable.
†
The P value was calculated with the use of the Fine–Gray subdistribution hazard model and Gray’s test.
‡
The P value was calculated with the use of the Cox proportional-hazards model and chi-square test.
§
Three patients received a diagnosis of therapy-related MDS but were found to have secondary AML before transplantation.
¶
Not all patients had a mutation in one of these genes or pathways.